Literature DB >> 12368584

Current concepts of pharmacotherapy in hypertension: ACE inhibitor-related angioedema: can angiotensin-receptor blockers be safely used?

Domenic A Sica1, Henry R Black.   

Abstract

Angioedema is a well-recognized side effect of angiotensin-converting enzyme (ACE) inhibitor therapy. Angioedema can also be seen with angiotensin receptor blocker therapy but much less frequently than is the case with ACE inhibitors. For unclear reasons, ACE inhibitor-related angioedema occurs more commonly in black patients. Angioedema can be life threatening but more times than not its occurrence can be managed with conservative treatment measures including discontinuation of the medication and/or administration of an antihistamine. Occasionally, epinephrine and/or steroid therapy may be warranted. In a patient having experienced ACE inhibitor-related angioedema, angiotensin receptor blockers should be used cautiously if at all. If angiotensin receptor blocker therapy is being considered in a patient with prior ACE inhibitor-related angioedema there should be some justification for the use. Such justification might include the presence of heart failure or proteinuric nephropathic states among other considerations. Copyright 2002 Le Jacq Communications, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12368584      PMCID: PMC8099384          DOI: 10.1111/j.1524-6175.2002.01509.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  45 in total

1.  Angioedema due to losartan.

Authors:  R Rupprecht; C Vente; A Gräfe; T Fuchs
Journal:  Allergy       Date:  1999-01       Impact factor: 13.146

2.  Angioedema due to ACE inhibitors: increased risk in patients of African origin.

Authors:  C R Gibbs; G Y Lip; D G Beevers
Journal:  Br J Clin Pharmacol       Date:  1999-12       Impact factor: 4.335

3.  Angioedema secondary to angiotensin-converting enzyme inhibitors.

Authors:  J P Pracy; J A McGlashan; R M Walsh; M J Gleeson
Journal:  J Laryngol Otol       Date:  1994-08       Impact factor: 1.469

4.  Different patterns of angioedema in patients with and without angiotensin-converting enzyme inhibitor therapy.

Authors:  H Herkner; A F Temmel; M Müllner; C Havel; M M Hirschl; J Kofler; A N Laggner
Journal:  Wien Klin Wochenschr       Date:  2001-03-15       Impact factor: 1.704

5.  Severe angioedema related to ACE inhibitors in patients with a history of idiopathic angioedema.

Authors:  N Orfan; R Patterson; M S Dykewicz
Journal:  JAMA       Date:  1990-09-12       Impact factor: 56.272

Review 6.  ACE inhibitor-induced angioedema of the intestine: Case report, incidence, pathophysiology, diagnosis and management.

Authors:  G Oudit; N Girgrah; J Allard
Journal:  Can J Gastroenterol       Date:  2001-12       Impact factor: 3.522

7.  Examination of baseline levels of carboxypeptidase N and complement components as potential predictors of angioedema associated with the use of an angiotensin-converting enzyme inhibitor.

Authors:  C Sigler; K Annis; K Cooper; H Haber; S Van deCarr
Journal:  Arch Dermatol       Date:  1997-08

8.  Angioneurotic edemas of the upper aerodigestive tract after ACE-inhibitor treatment.

Authors:  M Tisch; L Lampl; A Groh; H Maier
Journal:  Eur Arch Otorhinolaryngol       Date:  2002-05-24       Impact factor: 2.503

Review 9.  Angioedema: 5 years' experience, with a review of the disorder's presentation and treatment.

Authors:  C A Megerian; J E Arnold; M Berger
Journal:  Laryngoscope       Date:  1992-03       Impact factor: 3.325

10.  Isolated uvular angioedema associated with ACE inhibitor use.

Authors:  D C Kuo; R A Barish
Journal:  J Emerg Med       Date:  1995 May-Jun       Impact factor: 1.484

View more
  13 in total

1.  A case report looking at ACE inhibitors as the cause of angioedema during dental treatment.

Authors:  P Raval
Journal:  Br Dent J       Date:  2014-01       Impact factor: 1.626

Review 2.  Clinical pharmacokinetics of losartan.

Authors:  Domenic A Sica; Todd W B Gehr; Siddhartha Ghosh
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

3.  Allergic reaction related to ramipril use: a case report.

Authors:  Renata C Alencar; Roberta A Cobas; Marília B Gomes
Journal:  Diabetol Metab Syndr       Date:  2010-01-20       Impact factor: 3.320

4.  Case-control study evaluating competing risk factors for angioedema in a high-risk population.

Authors:  Rebecca J Kamil; Elina Jerschow; Patricia A Loftus; Melin Tan; Marvin P Fried; Richard V Smith; David Foster; Thomas J Ow
Journal:  Laryngoscope       Date:  2016-01-04       Impact factor: 3.325

5.  ACE Inhibitor-Related Angioedema: Are Your Patients at Risk?

Authors:  Michele B Kaufman
Journal:  P T       Date:  2013-03

Review 6.  Angiotensin receptor blockers: pharmacology, efficacy, and safety.

Authors:  Addison A Taylor; Helmy Siragy; Shawna Nesbitt
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-07-27       Impact factor: 3.738

7.  Direct renin inhibition--commonly asked questions.

Authors:  Domenic A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-11       Impact factor: 3.738

8.  The African American Study of Kidney Disease and Hypertension (AASK) trial: what more have we learned?

Authors:  Domenic A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2003 Mar-Apr       Impact factor: 3.738

9.  Hypertension and end-organ disease in African Americans: case presentations.

Authors:  Domenic A Sica
Journal:  J Clin Hypertens (Greenwich)       Date:  2004-04       Impact factor: 3.738

10.  Safety and efficacy of fimasartan in patients with arterial hypertension (Safe-KanArb study): an open-label observational study.

Authors:  Jeong Bae Park; Ki-Chul Sung; Seok-Min Kang; Eun Joo Cho
Journal:  Am J Cardiovasc Drugs       Date:  2013-02       Impact factor: 3.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.